, Cette association montre alors une potentialisation d'action entre

, On pourrait donc envisager d'utiliser ce type de combinaison en clinique pour les traitements des LAM en rechutes. Des essais précliniques similaires ont déjà été autorisés concernant d'autres cancers, tels que le gliome malin (17), Cette découverte ouvre des perspectives thérapeutiques majeurs dans les LAM

, IV) Références bibliographiques

, Pharmamémo Hématologie édition, 2017.

,

H. and H. Et, Al Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic-stem-and progenitor cells in acute myeloid leukemia (AML)

, Oncotarget, 2012.

. Marie-magdelaine-coudé, BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells, Oncotarget, 2015.

R. Lu, Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML), Front Oncol, 2017.

M. J. Veenstra, Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells, Oncotarget, 2016.

W. Fiskus, S. Sharma, and J. Qi, Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells, Mol Cancer Ther, 2014.

C. T. Ishida, BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma, Oncotarget, 2017.

D. Michael, Lung cancer epigenetics: from knowledge to applications, Seminars in Cancer Biology, 2017.

G. E. Winter, BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment, Molecular Cell, 2017.

W. Lee, Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer, Cell Biochem, 2018.

. Marie-magdelaine-coudé, BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells, Oncotarget, 2015.

T. Decker, Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1, Scientific reports, 2017.

J. E. , Bolden Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition, National instututes of health, 2014.

A. Puissant, Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer discovery, 2013.

V. Roe, The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia, 2016.

W. Fiskus, S. Sharma, and J. Qi, Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells, Mol Cancer Ther, 2014.

A. Nordigården, BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3, Blood Journal, 2016.